Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Fsd Pharma Inc Cl B
(NQ:
HUGE
)
0.0899
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Aug 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Fsd Pharma Inc Cl B
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder
March 22, 2023
From
FSD Pharma Inc.
Via
Business Wire
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
March 20, 2023
Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered
Via
Benzinga
Psychedelics Company Conducts Investigation Into Potential Naked Short Selling Of Its Stock
March 14, 2023
FSD Pharma Inc. (NASDAQ: HUGE) has renewed a service agreement with shareholder intelligence services provider ShareIntel LLC to assist in ongoing
Via
Benzinga
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Engages ShareIntel to Investigate Possible Naked Short Selling of Its Stock
March 14, 2023
Via
Investor Brand Network
FSD Pharma (Symbol: HUGE) Renews Shareholder Intelligence Services to Investigate Possible Naked Short Selling and Appeals to The Regulators and Oversight Bodies to Look Into The Short Selling Activity Of Its Stock
March 14, 2023
From
FSD Pharma Inc.
Via
Business Wire
Benzinga's Psychedelics Capital Conference: Meet An Unrivaled Group Of Advisors And Fund Partners
March 07, 2023
The upcoming Psychedelics Capital Conference constitutes Benzinga’s effort to provide an exclusive opportunity to meet, connect with and learn from some of the most knowledgeable people in the space.
Via
Benzinga
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
March 07, 2023
Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been...
Via
Benzinga
Here Are The Year's Highest Priced Psychedelics Stocks In US Markets
March 06, 2023
After everything that's happened in the last several years, we believe it's safe to say that the psychedelic renaissance is a reality, one that Benzinga has consistently reported on.
Via
Benzinga
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) News Discussed in Latest InvestmentPitch Media Video
March 01, 2023
Via
Investor Brand Network
Shark Tank's Kevin Harrington Will Provide Strategic Guidance To Major Psychedelics Company
February 28, 2023
Psychedelics biopharma company FSD Pharma Inc. (NASDAQ: HUGE)’s advisory board has a new member: the iconic entrepreneur and inventor of the infomercial Kevin Harrington.
Via
Benzinga
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Expands Advisory Board to Welcome Original ‘Shark’ and Visionary Kevin Harrington
February 28, 2023
Via
Investor Brand Network
Original “Shark” and Iconic Entrepreneur Kevin Harrington Joins FSD Pharma Advisory Board
February 28, 2023
From
FSD Pharma Inc.
Via
Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Interact with Leaders Pushing Boundaries of MS Research at Upcoming Forum
February 21, 2023
Via
Investor Brand Network
FSD Pharma Presenting Two Scientific Posters on Preclinical Toxicology and Efficacy Data of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2023 Forum
February 21, 2023
From
FSD Pharma Inc.
Via
Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Receives Confirmation of NASDAQ Compliance
February 15, 2023
Via
Investor Brand Network
FSD Pharma Regains Compliance with NASDAQ Continued Listing Requirements
February 15, 2023
From
FSD Pharma Inc.
Via
Business Wire
Psychedelics For Alcohol Use Disorder: Awakn Opens European Clinic, FSD Launches R&D Program
February 14, 2023
Awakn Opens Fourth European Clinic, Norway Takes Center Stage
Via
Benzinga
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Launches New Program Targeting Unmet Medical Needs for Alcohol Misuse
February 14, 2023
Via
Investor Brand Network
FSD Pharma Launches A New Research and Development Program Targeting Unmet Medical Needs for Alcohol Misuse
February 14, 2023
From
FSD Pharma Inc.
Via
Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Receipt of No Objection Letter from Health Canada Is Focus of Recent InvestmentPitch Media Video
February 09, 2023
Via
Investor Brand Network
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Receives Health Canada Regulatory Approval to Move Forward with Phase 1 Trial
February 07, 2023
Via
Investor Brand Network
FSD Pharma Receives Regulatory Clearance for Its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug Candidate
February 07, 2023
From
FSD Pharma Inc.
Via
Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Commences Recruitment in FSD201 Phase 2 Clinical Trial
January 30, 2023
Via
Investor Brand Network
Exposures
Product Safety
Recruiting Underway in FSD Pharma’s Phase 2 Trial of FSD-PEA (FSD201) for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)
January 30, 2023
From
FSD Pharma Inc.
Via
Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Spotlighted in InvestmentPitch Media Video Discussing Clinical Trial Application
January 19, 2023
Via
Investor Brand Network
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Submits Phase-1 Clinical Trial Application for Lucid-MS
January 17, 2023
Via
Investor Brand Network
FSD Pharma submits its phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigation
January 17, 2023
From
FSD Pharma Inc.
Via
Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board Authorized Share Repurchase Program
January 13, 2023
Via
Investor Brand Network
FSD Pharma Announces Share Repurchase Program
January 13, 2023
From
FSD Pharma Inc.
Via
Business Wire
6 Psychedelics Companies Take Action: Here Are The Latest, Major Announcements
January 10, 2023
Second week of 2023, and business is up and running. Let’s take a look at the announcements shared by some of the companies in the psychedelics space.
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.